Turkish biotech startups are on the rise


In 2020, the number of start-ups carrying out biotechnology activities increased to 499, and the amount allocated to research and development expenditures by these companies was 417.6 million.

The Turkish Statistical Institute (TUIK) also announced its 2020 biotechnology statistics.


Accordingly, the number of companies using biotechnology in their products or services has been determined.

And biotechnology research and development activities were implemented in Turkey last year as 499 companies, and this number was 363 in 2019.

When enterprises in this field are analyzed according to the number of employees and size groups, it is noted that there are 369 enterprises with 1-9 employees and 67 enterprises with 10-49 employees.

37 start-ups with 50-249 employees and 26 start-ups with 250 or more employees carried out biotechnology activities.

Last year, the technology most used in this field by start-ups carrying out biotechnology activities was “DNA/RNA”.


The number of interventions using the above technology was defined as 261, which was followed by “bioprocessing techniques” used by 155 companies and “tissue and cell culture engineering” techniques used by 139 institutions.

When examining the applications, it is noted that 41.3 percent of organizations implementing biotechnology activities in 2020 are related to human health (other treatments.

as well as synthetic substrates, diagnostic and drug delivery systems, etc.).

and 32.9 percent with agricultural biotechnology, and 24 percent for human health (using rDNA technology) to implement activities.

The number of startups offering biotechnology products in the market reached 302 in 2020.


It has been observed that 454 of the companies that announce their participation in biotechnology activities have already developed goods or services that require the use of biotechnology.

426 companies have already developed processes that require the use of biotechnology, and 415 organizations see biotechnology at the center of their activities or strategies.

Research and development expenditures for startups in 2020 amounted to 417 million 560,618 liras. These expenses amounted to 324 million and 462 thousand and 31 pounds in the previous year.

While the share of biotechnology research and development expenditures in research and development expenditures for financial and non-financial companies was 1.1 percent in 2019, this rate was recorded at 1.17 percent in 2020.

While 2,753 people worked in biotechnology activities last year, 47.7 percent of the employees were men and 52.3 percent were women.


It was also determined that 16.2 percent of employees hold a doctorate degree, and 22.2 percent have a master’s degree.

36.4 percent have a bachelor’s degree, 7.3 percent have a university education, and 17.9 percent have secondary education or a lower level of education.

According to biotech startups, the most significant obstacle to biotech research and development was “access to capital” at 60.9 percent.

It is followed by “access to qualified human resources” at 49.7 percent and “regulatory requirements” at 34.3 percent.


The biggest obstacle to the commercialization of biotechnology products was “international market access” (57.5 percent).

and “Regulatory Requirements” (53.9 percent), and “Access to Capital” (53.5 percent).